89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
European Journal of Nuclear Medicine and Molecular Imaging · 2023-06 · 50 (7) · 2068-2080
DOI: 10.1007/s00259-023-06164-w ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 02.03.2023. Verfasst von Iris H C Miedema und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Head and Neck Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive biomarkers are lacking. Here, we explored the potential use of the anti-LAG-3 antibody tracer [ 89 Zr]Zr-BI 754111 as a predictive imaging biomarker and investigated its target specific uptake as well as the correlation of its tumor uptake and the tumor immune infiltration.
Methods
Patients with head and neck ( N = 2) or lung cancer ( N = 4) were included in an imaging substudy of a phase 1 trial with BI 754091 (anti-PD-1) and BI 754111 (anti-LAG-3). After baseline tumor biopsy and [ 18 F]FDG-PET, patients were given 240 mg of BI 754091, followed 8 days later by administration of [ 89 Zr]Zr-BI 754111 (37 MBq, 4 mg). PET scans were performed 2 h, 96 h, and 144 h post-injection. To investigate target specificity, a second tracer administration was given two weeks later, this time with pre-administration of 40 ( N = 3) or 600 mg ( N = 3) unlabeled BI 754111, followed by PET scans at 96 h and 144 h post-injection. Tumor immune cell infiltration was assessed by immunohistochemistry and RNA sequencing.
Results
Tracer uptake in tumors was clearly visible at the 4-mg mass dose (tumor-to-plasma ratio 1.63 [IQR 0.37-2.89]) and could be saturated by increasing mass doses (44 mg: 0.67 [IQR 0.50–0.85]; 604 mg: 0.56 [IQR 0.42–0.75]), demonstrating target specificity. Tumor uptake correlated to immune cell-derived RNA signatures. Conclusions [ 89 Zr]Zr-BI-754111 PET imaging shows favorable technical and biological characteristics for developing a potential predictive imaging biomarker for LAG-3-directed therapies.
Trial registration
ClinicalTrials.gov , NCT03780725. Registered 19 December 2018
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.
- Imaging and Biomarkers, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.
- Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.
- Department of Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
- Department of Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88400, Biberach and der Riss, Germany.
- Cancer Biology and Immunology, Cancer Center Amsterdam, De Boelelaan 1117, 1018 HV, Amsterdam, the Netherlands.
ORCID-Profile: Iris H C Miedema
Zitieren
APA
Miedema, I. H. C., Huisman, M. C., Zwezerijnen, G. J. C., Grempler, R., Pitarch, A. P., Thiele, A., Hesse, R., Elgadi, M., Peltzer, A., Vugts, D. J., van Dongen, G. A. M. S., de Gruijl, T. D., Menke-van der Houven van Oordt, C. W., & Bahce, I. (2023). 89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC. European Journal of Nuclear Medicine and Molecular Imaging, 50(7), 2068-2080. https://doi.org/10.1007/s00259-023-06164-w
Vancouver
Miedema IHC, Huisman MC, Zwezerijnen GJC, Grempler R, Pitarch AP, Thiele A, et al. 89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC. European Journal of Nuclear Medicine and Molecular Imaging. 2023;50(7):2068-2080. doi:10.1007/s00259-023-06164-w
BibTeX
@article{Miedema2023,
author = {Miedema, Iris H C and Huisman, Marc C and Zwezerijnen, Gerben J C and Grempler, Rolf and Pitarch, Alejandro Perez and Thiele, Andrea and Hesse, Raphael and Elgadi, Mabrouk and Peltzer, Alexander and Vugts, Danielle J and van Dongen, Guus A M S and de Gruijl, Tanja D and Menke-van der Houven van Oordt, C Willemien and Bahce, Idris},
title = {89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2023},
volume = {50},
number = {7},
pages = {2068--2080},
doi = {10.1007/s00259-023-06164-w}
}
EUVIMED